<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="231">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238782</url>
  </required_header>
  <id_info>
    <org_study_id>D1532C00080</org_study_id>
    <nct_id>NCT02238782</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.</brief_title>
  <official_title>A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib With Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the absolute bioavailability of oral selumetinib in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Absolute Bioavailability</measure>
    <time_frame>0 to 72 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To calculate absolute bioavailability we used the formula: Area Under the Curve (oral dose)/Area Under the Curve (intravenous dose)*100</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy Volunteers Bioavailability Study</condition>
  <arm_group>
    <arm_group_label>selumetinib 75mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules of 25 mg administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib 75mg single dose</intervention_name>
    <description>3 capsules of 25 mg given as a single dose</description>
    <arm_group_label>selumetinib 75mg single dose</arm_group_label>
    <other_name>Selumetinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[14C] selumetinib IV solution</intervention_name>
    <description>single, radiolabeled, IV (infused), microdose (80 Î¼g) of [14C] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose</description>
    <arm_group_label>selumetinib 75mg single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of written informed consent

          2. Healthy male volunteers aged 18 to 65

          3. Male volunteers with sexual partners who are pregnant or who could become pregnant
             should use two highly effective methods of contraception (including one barrier
             method) for at least 14 days after completing the study and should avoid sperm
             donation for 14 days after study completion.

          4. Body mass index between 18 and 30 kg/m2 and weighing between 50 and 100 kg.

          5. Use no nicotine containing products for at least 3 months prior to screening with a
             negative cotinine screen at screening and Day 1 (Visit 2)

          6. Calculated creatinine clearance greater than 50 mL/min using Cockcroft Gault formula.

        Exclusion Criteria:

          1. Involvement in the planning and/or conduct of the study

          2. Previous enrolment for treatment in the present study

          3. Japanese or non Japanese Asian or Indian ethnicity.

          4. Any one parent or grandparent is Japanese or non-Japanese Asian or Indian.

          5. Treatment with another new chemical entity or participation in any other clinical
             study that included drug treatment within at least 3 months

          6. Participation in another clinical study involving administration of [14C]
             radioactivity within 1 year.

          7. Current or past history of central serious retinopathy or retinal vein thrombosis,
             intraocular pressure greater than 21 mmHg or uncontrolled glaucoma.

          8. Any clinically significant disease or disorder which, may put the volunteer at risk
             because of participation in the study, influence the study result or influence the
             volunteer's ability to participate in the study.

          9. Any clinically relevant abnormal findings in physical examination, haematology,
             clinical chemistry, urinalysis, vital signs or 12 lead ECG at Visit 1, which may put
             the volunteer at risk because of his participation in the study.

         10. Use of drugs with enzyme inducing properties such as St John's Wort within 4 weeks
             prior to the administration of the investigational product

         11. Use of any other prescribed medicine and over the counter drugs within 2 week or 5
             times the half life, whichever is longer prior to the administration of the
             investigational product up to and including the follow up visit (Visit 4), with the
             exception of occasional use of paracetamol or ibuprofen and over the counter
             adrenergic nasal spray. No medications known to prolong the QT/corrected QT interval
             are allowed.

         12. Excessive intake of caffeine containing drinks or food

         13. Any intake of grapefruit and Seville oranges including products containing grapefruit
             or Seville oranges within 7 days of the admission on Day -1.

         14. History of severe allergy/hypersensitivity or ongoing clinically important
             allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar
             chemical structure or class to Selumetinib.

         15. Plasma donation within 1 month of screening (Visit 1) or any blood donation or blood
             loss greater than 500 mL during the 3 months prior to screening (Visit 1).

         16. History of or current alcohol or drug abuse.

         17. A suspected or manifested infection according to the International Air Transport
             Association Categories A and B infectious substances.

         18. Positive results on screening tests for HIV and/or hepatitis B and/or hepatitis C.

         19. Baseline LVEF &lt;55% measured by echocardiography.

         20. Planned inpatient surgery, dental procedure or hospitalisation during the study.

         21. Healthy male volunteers who in the opinion of the Principal Investigator, should not
             participate in the study.

         22. Judgment by Principal Investigator that the volunteer should not participate in the
             study if they have ongoing or recent minor medical complaints that may interfere with
             the interpretation of study data or are considered unlikely to comply with study
             procedures, restrictions, and requirements.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Mair</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 4, 2016</lastchanged_date>
  <firstreceived_date>August 8, 2014</firstreceived_date>
  <firstreceived_results_date>October 6, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>I phase</keyword>
  <keyword>AZD6244</keyword>
  <keyword>cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>21 subjects were enrolled, 12 of these subjects went on to receive treatment</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Selumetinib</title>
          <description>Patients received a single oral dose of selumetinib 75mg followed by IV carbon 14 selumetinib (80 micrograms) 1 hour 15 minutes after receiving the oral dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Treated</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Selumetinib</title>
          <description>Patients received a single oral dose of selumetinib 75mg followed by IV carbon 14 selumetinib (80 micrograms) 1 hour 15 minutes after receiving the oral dose.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42" spread="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Bioavailability</title>
        <description>To calculate absolute bioavailability we used the formula: Area Under the Curve (oral dose)/Area Under the Curve (intravenous dose)*100</description>
        <time_frame>0 to 72 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Selumetinib</title>
            <description>Selumetinib 75 mg oral followed by IV carbon 14 selumetinib (80 micrograms) administered 1 hour 15 minutes after the oral dose.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Absolute Bioavailability</title>
            <description>To calculate absolute bioavailability we used the formula: Area Under the Curve (oral dose)/Area Under the Curve (intravenous dose)*100</description>
            <units>% of bioavailability</units>
            <param>Geometric Mean</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62.1" lower_limit="60.1" upper_limit="64.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Selumetinib</title>
          <description>Patients received a single oral dose of selumetinib 75mg followed by IV carbon 14 selumetinib (80 micrograms) 1 hour 15 minutes after receiving the oral dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Head Ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gabriella Mariani</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 7818 523 899</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
